Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment. (1st January 2014)

• Record Type: Journal Article
• Authors: Assaf, Mahmoud S.; Laille, Eric; Liu, Liangang; O'Mara, Edward; Wu, Anfan; Palmisano, Maria; Marbury, Thomas C.; Preston, Richard A.
• Is Part Of: International journal of medical engineering and informatics. Volume 6:Number 2(2014)
• Page Start: 100
• Page End: 114
• Publication Date: 2014-01-01
• Subjects: hepatic impairment -- hepatic metabolism -- pharmacokinetics -- PK -- phosphodiesterase 4 -- PDE4 -- apremilast; 610.2805
• Languages: English
• ISSNs: 1755-0653

Abstract

Apremilast (CC-10004), a PDE4 enzyme inhibitor, is under clinical development for the treatment of inflammatory immune-mediated disorders. Since apremilast is extensively metabolised via multiple routes, impact of hepatic impairment on the pharmacokinetics (PK) of apremilast and M12 metabolite was evaluated. Thirty-two subjects were enrolled in a two-centre, open-label, and single-dose study. Subjects with moderate hepatic impairment and their healthy matches received a single 30-mg dose and subjects with severe hepatic impairment and their healthy matches received a single 20-mg dose of apremilast. Plasma concentrations of apremilast and M12 were measured, PK parameters calculated, and statistically compared. During the study, single doses of apremilast were well tolerated, with no clinically meaningful safety findings observed. PK parameters were comparable between hepatic impaired and healthy subjects, and there was no evidence to suggest that the PK of apremilast is affected by moderate and severe hepatic impairment. Therefore, no dose adjustment is required.